共 155 条
- [1] Kishan AU(2019)Long-term outcomes of stereotactic body radiotherapy for low-risk and intermediate-risk prostate cancer JAMA Netw Open 2 e188006-90
- [2] Dang A(2019)Two StereoTactic ablative radiotherapy treatments for localized prostate cancer (2STAR): results from a prospective clinical trial Radiother Oncol 135 86-789
- [3] Katz AJ(2019)Stereotactic body radiation therapy for localized prostate cancer: a systematic review and meta-analysis of over 6000 patients treated on prospective studies Int J Radiat Oncol Biol Phys 104 778-395
- [4] Alayed Y(2019)Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial Lancet (London, England) 394 385-68
- [5] Cheung P(2013)Stereotactic body radiotherapy for localized prostate cancer: disease control and quality of life at 6 years Radiat Oncol 8 118-1482
- [6] Chu W(2017)What is the best way to radiate the prostate in 2016? Urol Oncol 35 59-941
- [7] Jackson WC(2015)Comparison of onboard low-field magnetic resonance imaging versus onboard computed tomography for anatomy visualization in radiotherapy Acta Oncol (Madr) 54 1474-394
- [8] Silva J(2019)First 500 fractions delivered with a magnetic resonance-guided radiotherapy system: initial experience Cureus 104 933-1060
- [9] Hartman HE(2019)Role of on-table plan adaptation in MR-guided ablative radiation therapy for central lung tumors Int J Radiat Oncol Biol Phys 26 387-94
- [10] Widmark A(2016)BRAF inhibitor and stereotactic radiosurgery is associated with an increased risk of radiation necrosis Melanoma Res 17 1047-1098